AstraZeneca

Plagued by delays, AstraZeneca HQ costs soar to £750M as it edges toward 2020 completion
Endpoints
Wed, 06/12/19 - 09:38 am
AstraZeneca
headquarters
ADA: AstraZeneca's Farxiga scores in kidney outcomes study
Fierce Pharma
Mon, 06/10/19 - 09:44 am
AstraZeneca
ADA
Farxiga
clinical trials
renal disease
AstraZeneca ends another Calquence trial early
Pharmaforum
Thu, 06/6/19 - 09:55 am
AstraZeneca
CLL
Calquence
clinical trials
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
Xconomy
Wed, 06/5/19 - 10:43 am
ASCO 2019
cancer
immunotherapy
diagnostics
Veracyte
Grail
Moderna Therapeutics
Amgen
Nektar Therapeutics
Blueprint Medicines
Merck
AstraZeneca
Roche
breast cancer
ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'
Fierce Pharma
Tue, 06/4/19 - 12:18 pm
ASCO 2019
Merck
Keytruda
FDA
Pfizer
AstraZeneca
Regeneron
Libtayo
Venclexta
Gazyva
AstraZeneca scouts replacements for longtime chairman Johansson: report
Fierce Pharma
Tue, 06/4/19 - 11:05 am
AstraZeneca
Leif Johansson
ASCO 2019 – The results of clinical practices changing phase III studies
Pharmaforum
Mon, 06/3/19 - 11:32 pm
clinical trials
ASCO 2019
Merck
AstraZeneca
Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC
Pharmaceutical Business Review
Mon, 06/3/19 - 11:29 am
AstraZeneca
Imfinzi
ASCO 2019
non-small cell lung cancer
ASCO 2019 day three
Pharmaforum
Sun, 06/2/19 - 01:09 pm
ASCO 2019
Merck
AstraZeneca
pancreatic cancer
Novartis
alpelisib
Roche
entrectinib
AZ/Merck & Co reveal data supporting PARP drug in prostate cancer
Pharmaforum
Sat, 06/1/19 - 12:43 pm
ASCO 2019
AstraZeneca
Merck
prostate cancer
olaparib
ASCO 2019 day one
Pharmaforum
Fri, 05/31/19 - 11:46 am
ASCO 2019
JNJ
Erleada
AstraZeneca
Merck
Lynparza
prostate cancer
ASCO 2019 Preview: Presentations to Keep An Eye On
BioSpace
Thu, 05/30/19 - 09:35 am
ASCO 2019
Novartis
Oncoceutics
OncoNano Medicine
AstraZeneca
Inovio Pharma stock slips as AstraZeneca unit scales back agreement
Marketwatch
Wed, 05/29/19 - 10:32 am
Inovio
AstraZeneca
MedImmune
MEDI0457
AstraZeneca pivots to early-stage cancer in search of a niche
Fierce Pharma
Tue, 05/28/19 - 10:31 am
AstraZeneca
cancer
Jose Baselga
[sponsored] Life Sciences Matchmaker SOURCE EXPLORER Passes 3,000-Client Milestone

CP Wire
Tue, 05/28/19 - 10:26 am
life sciences
Source Explorer
Gilead Sciences
Roche
Mylan
Biogen
Genentech
AstraZeneca
[sponsored] Life Sciences Matchmaker SOURCE EXPLORER Passes 3,000-Client Milestone

Tue, 05/28/19 - 10:24 am
life sciences
Source Explorer
Gilead Sciences
Roche
Mylan
Biogen
Genentech
AstraZeneca
AstraZeneca says Symbicort as anti-inflammatory reliever reduces attacks in mild asthma
Pharmaceutical Business Review
Tue, 05/21/19 - 10:41 am
AstraZeneca
Symbicort Turbohaler
asthma
mild asthma
AstraZeneca's Fasenra offers severe asthma patients 2 years of benefits: analysis
Fierce Pharma
Mon, 05/20/19 - 10:12 am
AstraZeneca
Fasenra
severe asthma
asthma
clinical trials
New insight into a struggling AstraZeneca anti-VEGF drug could expand its use in cancer
Fierce Biotech
Fri, 05/17/19 - 07:20 pm
AstraZeneca
Avastin
anti-VEGF
cediranib
Can a little known drug in AstraZeneca's pipeline make a comeback as a PARP add-on? Yale scientists explain how
Endpoints
Thu, 05/16/19 - 11:51 am
AstraZeneca
cediranib
ovarian cancer
Yale
PARP inhibitors

Pages